complement 3 glomerulopathy
Jul 29, 2025
Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency; Apellis Wins FDA Approval for EMPAVELI in C3G and IC-MPGN Treatment; FDA Approves PTC Therapeutics’ Sephience for Phenylketonuria; MAIA Biotechnology’s Ateganosine Gets FDA Fast Track for Non-Small Cell Lung Cancer; Entera Bio Gets FDA Nod on BMD as Primary Endpoint for Phase III Osteoporosis Study
Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency Ascendis Pharma A/S announced that the FDA has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of adult growth hormone deficiency (GHD). Already approved for pediatric GHD since 2021, SKYTROFA is a once-weekly prodrug of ...
Read More...
Feb 19, 2024
Advancements in Complement 3 Glomerulopathy (C3G) Treatment: Exploring Upcoming Anti-Complements
Complement 3 glomerulopathy (C3G) is a form of glomerular disease where there’s a notable presence of C3 complement component deposits in the glomeruli. These deposits occur without significant amounts of immunoglobulin and without the deposition of C1q and C4. The buildup of C3, without much classical or lectin co...
Read More...
Nov 09, 2020
Key Pharma Players Transforming the Complement 3 Glomerulopathy Market Landscape
Rare renal disorders are the fifth most prominent reason behind the cause of end-stage kidney disease (ESKD), ultimately leading to kidney failure, and damage to other tissues. Among such rare kidney diseases, one is complement 3 glomerulopathy (C3G). Albeit rare, the total diagnosed C3G prevalent population ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
